Rasika Kalamegham, PhD, is a Group Director, U.S. Regulatory Policy at Genentech, a Member of the Roche Group. Prior to joining Genentech, she worked in increasingly senior positions at Friends of Cancer Research (FoCR), The Pew Charitable Trusts and The American Association for Cancer Research (AACR). She has focused her policy efforts primarily on oncology, antibiotics and diagnostics. Her efforts have led to several important regulatory policy outcomes including FDA guidance on Codevelopment of Two or More New Investigational Drugs for Use in Combination, passage of the Generating Antibiotics Incentives Now or GAIN Act, the Blueprint PD-L1 IHC Assay Comparison Project and others. She is a geneticist by training and completed her post-doctoral training at the NIH.